Clarification4 Nov 2026, 11:47 am
Dr Reddy's Clarifies US FDA Nod for HIV Prevention Shot
AI Summary
Dr Reddy's Laboratories has clarified a news item regarding its generic HIV prevention shot receiving US FDA tentative approval. The company confirmed that the news pertains to its press release dated November 2, 2026, which announced the U.S. FDA's tentative approval for its twice-yearly injectable lenacapavir. This drug aims to advance access to HIV prevention across 120 countries outside the US. Dr Reddy's stated that this matter does not constitute a material event requiring disclosure under Regulation 30 of the SEBI Listing Regulations, emphasizing their commitment to timely disclosures of material information.
Key Highlights
- Dr Reddy's confirms US FDA tentative approval for HIV prevention shot.
- Drug targets 120 countries outside the US.
- Company clarifies news item does not require material disclosure.
- Confirms adherence to SEBI Listing Regulations for disclosures.
Price Impact
More from DRREDDY